154 related articles for article (PubMed ID: 30975911)
1. FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways.
Wu M; Li L; Hamaker M; Small D; Duffield AS
Haematologica; 2019 Dec; 104(12):2418-2428. PubMed ID: 30975911
[TBL] [Abstract][Full Text] [Related]
2. Natural small molecule triptonide inhibits lethal acute myeloid leukemia with FLT3-ITD mutation by targeting Hedgehog/FLT3 signaling.
Xu Y; Wang P; Li M; Wu Z; Li X; Shen J; Xu R
Biomed Pharmacother; 2021 Jan; 133():111054. PubMed ID: 33254022
[TBL] [Abstract][Full Text] [Related]
3. Shikonin Exerts an Antileukemia Effect against FLT3-ITD Mutated Acute Myeloid Leukemia Cells via Targeting FLT3 and Its Downstream Pathways.
Zhao MN; Su L; Song F; Wei ZF; Qin TX; Zhang YW; Li W; Gao SJ
Acta Haematol; 2024; 147(3):310-324. PubMed ID: 37926079
[TBL] [Abstract][Full Text] [Related]
4. FLT3-selective PROTAC: Enhanced safety and increased synergy with Venetoclax in FLT3-ITD mutated acute myeloid leukemia.
Tan Y; Xin L; Wang Q; Xu R; Tong X; Chen G; Ma L; Yang F; Jiang H; Zhang N; Wu J; Li X; Guo X; Wang C; Zhou H; Zhou F
Cancer Lett; 2024 Jun; 592():216933. PubMed ID: 38705564
[TBL] [Abstract][Full Text] [Related]
5. Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia.
Lam SS; Ho ES; He BL; Wong WW; Cher CY; Ng NK; Man CH; Gill H; Cheung AM; Ip HW; So CC; Tamburini J; So CW; Ho DN; Au CH; Chan TL; Ma ES; Liang R; Kwong YL; Leung AY
Sci Transl Med; 2016 Oct; 8(359):359ra129. PubMed ID: 27708062
[TBL] [Abstract][Full Text] [Related]
6. CALCRL knockdown suppresses cancer stemness and chemoresistance in acute myeloid leukemia with FLT3-ITD and DNM3TA-R882 double mutations.
Tang S; Zhu H; Sheng L; Mu Q; Wang Y; Xu K; Zhou M; Xu Z; Wu A; Ouyang G
Drug Dev Res; 2024 Feb; 85(1):e22137. PubMed ID: 38349260
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.
Mathew NR; Baumgartner F; Braun L; O'Sullivan D; Thomas S; Waterhouse M; Müller TA; Hanke K; Taromi S; Apostolova P; Illert AL; Melchinger W; Duquesne S; Schmitt-Graeff A; Osswald L; Yan KL; Weber A; Tugues S; Spath S; Pfeifer D; Follo M; Claus R; Lübbert M; Rummelt C; Bertz H; Wäsch R; Haag J; Schmidts A; Schultheiss M; Bettinger D; Thimme R; Ullrich E; Tanriver Y; Vuong GL; Arnold R; Hemmati P; Wolf D; Ditschkowski M; Jilg C; Wilhelm K; Leiber C; Gerull S; Halter J; Lengerke C; Pabst T; Schroeder T; Kobbe G; Rösler W; Doostkam S; Meckel S; Stabla K; Metzelder SK; Halbach S; Brummer T; Hu Z; Dengjel J; Hackanson B; Schmid C; Holtick U; Scheid C; Spyridonidis A; Stölzel F; Ordemann R; Müller LP; Sicre-de-Fontbrune F; Ihorst G; Kuball J; Ehlert JE; Feger D; Wagner EM; Cahn JY; Schnell J; Kuchenbauer F; Bunjes D; Chakraverty R; Richardson S; Gill S; Kröger N; Ayuk F; Vago L; Ciceri F; Müller AM; Kondo T; Teshima T; Klaeger S; Kuster B; Kim DDH; Weisdorf D; van der Velden W; Dörfel D; Bethge W; Hilgendorf I; Hochhaus A; Andrieux G; Börries M; Busch H; Magenau J; Reddy P; Labopin M; Antin JH; Henden AS; Hill GR; Kennedy GA; Bar M; Sarma A; McLornan D; Mufti G; Oran B; Rezvani K; Shah O; Negrin RS; Nagler A; Prinz M; Burchert A; Neubauer A; Beelen D; Mackensen A; von Bubnoff N; Herr W; Becher B; Socié G; Caligiuri MA; Ruggiero E; Bonini C; Häcker G; Duyster J; Finke J; Pearce E; Blazar BR; Zeiser R
Nat Med; 2018 Mar; 24(3):282-291. PubMed ID: 29431743
[TBL] [Abstract][Full Text] [Related]
8. The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML.
Qiao X; Ma J; Knight T; Su Y; Edwards H; Polin L; Li J; Kushner J; Dzinic SH; White K; Wang J; Lin H; Wang Y; Wang L; Wang G; Taub JW; Ge Y
Blood Cancer J; 2021 Jun; 11(6):111. PubMed ID: 34099621
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of NRF2 signaling overcomes acquired resistance to arsenic trioxide in FLT3-mutated Acute Myeloid Leukemia.
Jebanesan DZP; Illangeswaran RSS; Rajamani BM; Vidhyadharan RT; Das S; Bijukumar NK; Balakrishnan B; Mathews V; Velayudhan SR; Balasubramanian P
Ann Hematol; 2024 Jun; 103(6):1919-1929. PubMed ID: 38630133
[TBL] [Abstract][Full Text] [Related]
10. Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia.
Stockard B; Garrett T; Guingab-Cagmat J; Meshinchi S; Lamba J
Sci Rep; 2018 Apr; 8(1):5534. PubMed ID: 29615816
[TBL] [Abstract][Full Text] [Related]
11. A combinatorial therapeutic approach to enhance FLT3-ITD AML treatment.
Long J; Chen X; Shen Y; Lei Y; Mu L; Wang Z; Xiang R; Gao W; Wang L; Wang L; Jiang J; Zhang W; Lu H; Dong Y; Ding Y; Zhu H; Hong D; Sun YE; Hu J; Liang A
Cell Rep Med; 2023 Nov; 4(11):101286. PubMed ID: 37951217
[TBL] [Abstract][Full Text] [Related]
12. Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia.
He BL; Yang N; Man CH; Ng NK; Cher CY; Leung HC; Kan LL; Cheng BY; Lam SS; Wang ML; Zhang CX; Kwok H; Cheng G; Sharma R; Ma AC; So CW; Kwong YL; Leung AY
EMBO Mol Med; 2020 Apr; 12(4):e10895. PubMed ID: 32134197
[TBL] [Abstract][Full Text] [Related]
13. Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia.
Pillinger G; Abdul-Aziz A; Zaitseva L; Lawes M; MacEwan DJ; Bowles KM; Rushworth SA
Sci Rep; 2015 Aug; 5():12949. PubMed ID: 26292723
[TBL] [Abstract][Full Text] [Related]
14. Microenvironmental CXCL12 deletion enhances Flt3-ITD acute myeloid leukemia stem cell response to therapy by reducing p38 MAPK signaling.
Anderson NR; Sheth V; Li H; Harris MW; Qiu S; Crossman DK; Kumar H; Agarwal P; Nagasawa T; Paterson AJ; Welner RS; Bhatia R
Leukemia; 2023 Mar; 37(3):560-570. PubMed ID: 36550214
[TBL] [Abstract][Full Text] [Related]
15. Depalmitoylation rewires FLT3-ITD signaling and exacerbates leukemia progression.
Lv K; Ren JG; Han X; Gui J; Gong C; Tong W
Blood; 2021 Dec; 138(22):2244-2255. PubMed ID: 34111291
[TBL] [Abstract][Full Text] [Related]
16. Leukemic mutation FLT3-ITD is retained in dendritic cells and disrupts their homeostasis leading to expanded Th17 frequency.
Flynn PA; Long MD; Kosaka Y; Long N; Mulkey JS; Coy JL; Agarwal A; Lind EF
Front Immunol; 2024; 15():1297338. PubMed ID: 38495876
[TBL] [Abstract][Full Text] [Related]
17. Treatment-induced arteriolar revascularization and miR-126 enhancement in bone marrow niche protect leukemic stem cells in AML.
Zhang B; Nguyen LXT; Zhao D; Frankhouser DE; Wang H; Hoang DH; Qiao J; Abundis C; Brehove M; Su YL; Feng Y; Stein A; Ghoda L; Dorrance A; Perrotti D; Chen Z; Han A; Pichiorri F; Jin J; Jovanovic-Talisman T; Caligiuri MA; Kuo CJ; Yoshimura A; Li L; Rockne RC; Kortylewski M; Zheng Y; Carlesso N; Kuo YH; Marcucci G
J Hematol Oncol; 2021 Aug; 14(1):122. PubMed ID: 34372909
[TBL] [Abstract][Full Text] [Related]
18. Blockade of de novo pyrimidine biosynthesis triggers autophagic degradation of oncoprotein FLT3-ITD in acute myeloid leukemia.
Ma H; Cui J; Liu Z; Fang W; Lu S; Cao S; Zhang Y; Chen JA; Lu L; Xie Q; Wang Y; Huang Y; Li K; Tong H; Huang J; Lu W
Oncogene; 2023 Nov; 42(45):3331-3343. PubMed ID: 37752234
[TBL] [Abstract][Full Text] [Related]
19. FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia.
Sung PJ; Selvam M; Riedel SS; Xie HM; Bryant K; Manning B; Wertheim GB; Kulej K; Pham L; Bowman RL; Peresie J; Nemeth MJ; Levine RL; Garcia BA; Meyer SE; Sidoli S; Bernt KM; Carroll M
Leukemia; 2024 Feb; 38(2):291-301. PubMed ID: 38182819
[TBL] [Abstract][Full Text] [Related]
20. Cytoplasmic DROSHA and non-canonical mechanisms of MiR-155 biogenesis in FLT3-ITD acute myeloid leukemia.
Nguyen LXT; Zhang B; Hoang DH; Zhao D; Wang H; Wu H; Su YL; Dong H; Rodriguez-Rodriguez S; Armstrong B; Ghoda LY; Perrotti D; Pichiorri F; Chen J; Li L; Kortylewski M; Rockne RC; Kuo YH; Khaled S; Carlesso N; Marcucci G
Leukemia; 2021 Aug; 35(8):2285-2298. PubMed ID: 33589748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
